Literature DB >> 15837620

Structural basis for inhibition of the epidermal growth factor receptor by cetuximab.

Shiqing Li1, Karl R Schmitz, Philip D Jeffrey, Jed J W Wiltzius, Paul Kussie, Kathryn M Ferguson.   

Abstract

Recent structural studies of epidermal growth factor receptor (EGFR) family extracellular regions have identified an unexpected mechanism for ligand-induced receptor dimerization that has important implications for activation and inhibition of these receptors. Here we describe the 2.8 angstroms resolution X-ray crystal structure of the antigen binding (Fab) fragment from cetuximab (Erbitux), an inhibitory anti-EGFR antibody, in complex with the soluble extracellular region of EGFR (sEGFR). The sEGFR is in the characteristic "autoinhibited" or "tethered" inactive configuration. Cetuximab interacts exclusively with domain III of sEGFR, partially occluding the ligand binding region on this domain and sterically preventing the receptor from adopting the extended conformation required for dimerization. We suggest that both these effects contribute to potent inhibition of EGFR activation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15837620     DOI: 10.1016/j.ccr.2005.03.003

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  358 in total

1.  Targeting the dimerization of epidermal growth factor receptors with small-molecule inhibitors.

Authors:  Robert Y C Yang; Katherine S Yang; Linda J Pike; Garland R Marshall
Journal:  Chem Biol Drug Des       Date:  2010-05-04       Impact factor: 2.817

2.  Epidermal growth factor receptor downregulation by small heterodimeric binding proteins.

Authors:  Benjamin J Hackel; Jason R Neil; Forest M White; K Dane Wittrup
Journal:  Protein Eng Des Sel       Date:  2011-12-09       Impact factor: 1.650

3.  Finding the missing links in EGFR.

Authors:  Nicholas J Bessman; Mark A Lemmon
Journal:  Nat Struct Mol Biol       Date:  2012-01-05       Impact factor: 15.369

Review 4.  Understanding resistance to EGFR inhibitors-impact on future treatment strategies.

Authors:  Deric L Wheeler; Emily F Dunn; Paul M Harari
Journal:  Nat Rev Clin Oncol       Date:  2010-06-15       Impact factor: 66.675

Review 5.  Mechanisms of tumor resistance to EGFR-targeted therapies.

Authors:  Elizabeth A Hopper-Borge; Rochelle E Nasto; Vladimir Ratushny; Louis M Weiner; Erica A Golemis; Igor Astsaturov
Journal:  Expert Opin Ther Targets       Date:  2009-03       Impact factor: 6.902

6.  Simulation of homology models for the extracellular domains (ECD) of ErbB3, ErbB4 and the ErbB2-ErbB3 complex in their active conformations.

Authors:  Juan Felipe Franco-Gonzalez; Javier Ramos; Victor L Cruz; Javier Martínez-Salazar
Journal:  J Mol Model       Date:  2012-10-23       Impact factor: 1.810

Review 7.  Current role of EGF receptor monoclonal antibodies and tyrosine kinase inhibitors in the management of head and neck squamous cell carcinoma.

Authors:  Ana Markovic; Christine H Chung
Journal:  Expert Rev Anticancer Ther       Date:  2012-09       Impact factor: 4.512

8.  Targeting the tumor microenvironment with interferon-β bridges innate and adaptive immune responses.

Authors:  Xuanming Yang; Xunmin Zhang; May Lynne Fu; Ralph R Weichselbaum; Thomas F Gajewski; Yajun Guo; Yang-Xin Fu
Journal:  Cancer Cell       Date:  2014-01-13       Impact factor: 31.743

9.  Balancing Selectivity and Efficacy of Bispecific Epidermal Growth Factor Receptor (EGFR) × c-MET Antibodies and Antibody-Drug Conjugates.

Authors:  Carolin Sellmann; Achim Doerner; Christine Knuehl; Nicolas Rasche; Vanita Sood; Simon Krah; Laura Rhiel; Annika Messemer; John Wesolowski; Mark Schuette; Stefan Becker; Lars Toleikis; Harald Kolmar; Bjoern Hock
Journal:  J Biol Chem       Date:  2016-09-30       Impact factor: 5.157

Review 10.  Mechanisms of action of therapeutic antibodies for cancer.

Authors:  J M Redman; E M Hill; D AlDeghaither; L M Weiner
Journal:  Mol Immunol       Date:  2015-04-23       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.